TumorPlex and Allele Specific Multiplex Sequencing (ASMS)

TumorPlex is a platform technology that detects single somatic nucleotide polymorphisms from FFPE (formalin fixed, paraffin embedded) samples. This platform technology utilizes Allele Specific Multiplex Sequencing (ASMS) technology as part of the process. ASMS uses proprietary allele specific sequencing primers to detect mutations in cancer samples (e.g. FFPE and fine needle aspiration biopsies) at 1,000 times lower concentration than presently used methods such as Next Generation Sequencing (NGS) and Real Time PCR.

Dr Roger Hodkinson


MutantDx Inc.

17204 106A Avenue
Edmonton, Alberta
Canada T5S 1E6